These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3661762)

  • 21. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The BPRS in assessing symptom correlates of cerebral ventricular enlargement in acute and chronic schizophrenia.
    Bishop RJ; Golden CJ; MacInnes WD; Chu CC; Ruedrich SL; Wilson J
    Psychiatry Res; 1983 Jul; 9(3):225-31. PubMed ID: 6604928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Schizophrenic symptoms and deterioration. Relation to computed tomographic findings.
    Pandurangi AK; Bilder RM; Rieder RO; Mukherjee S; Hamer RM
    J Nerv Ment Dis; 1988 Apr; 176(4):200-6. PubMed ID: 3351498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ventricle-to-brain ratio and symptoms at the onset of first-break schizophrenia.
    Holsenbeck LS; Davidson LM; Hostetter RE; Casanova MF; Taylor DO; Kelley CT; Perrotta C; Borison RL; Diamond B
    Schizophr Bull; 1992; 18(3):427-35. PubMed ID: 1411330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lateral ventricular enlargement in schizotypal personality disorder.
    Siever LJ; Rotter M; Losonczy M; Guo SL; Mitropoulou V; Trestman R; Apter S; Zemishlany Z; Silverman J; Horvath TB
    Psychiatry Res; 1995 Jul; 57(2):109-18. PubMed ID: 7480378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroanatomic differences among cognitive and symptom subtypes of schizophrenia.
    Allen DN; Seaton BE; Goldstein G; Sanders RD; Gurklis JA; Peters JL; van Kammen DP
    J Nerv Ment Dis; 2000 Jun; 188(6):381-4. PubMed ID: 10890348
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical correlates of decreased anteroposterior metabolic gradients in positron emission tomography (PET) of schizophrenic patients.
    DeLisi LE; Buchsbaum MS; Holcomb HH; Dowling-Zimmerman S; Pickar D; Boronow J; Morihisa JM; van Kammen DP; Carpenter W; Kessler R
    Am J Psychiatry; 1985 Jan; 142(1):78-81. PubMed ID: 3871312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risperidone in the treatment of schizophrenia.
    Marder SR; Meibach RC
    Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of response to lithium in patients with psychoses.
    Schexnayder LW; Hirschowitz J; Sautter FJ; Garver DL
    Am J Psychiatry; 1995 Oct; 152(10):1511-3. PubMed ID: 7573592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age and duration of illness as predictors of ventricular brain ratio (VBR) size in chronic schizophrenic patients. A stepwise regression analysis study.
    Rossi A; Stratta P; Casacchia M; D'Albenzio L; Schiazza G; De Donatis M
    Acta Psychiatr Scand; 1987 Sep; 76(3):256-60. PubMed ID: 3673652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes.
    Marder SR; Glynn SM; Wirshing WC; Wirshing DA; Ross D; Widmark C; Mintz J; Liberman RP; Blair KE
    Am J Psychiatry; 2003 Aug; 160(8):1405-12. PubMed ID: 12900301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive and negative symptoms. Relation to familial transmission of schizophrenia.
    Baron M; Gruen RS; Romo-Gruen JM
    Br J Psychiatry; 1992 Nov; 161():610-4. PubMed ID: 1422608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acutely psychotic patients receiving high-dose haloperidol therapy.
    Remington G; Pollock B; Voineskos G; Reed K; Coulter K
    J Clin Psychopharmacol; 1993 Feb; 13(1):41-5. PubMed ID: 8486816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can computerised tomography be used to predict early treatment response in schizophrenia?
    Schröder J; Geider FJ; Sauer H
    Br J Psychiatry Suppl; 1993 Sep; (21):13-5. PubMed ID: 8105813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 38. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
    Ko GN; Korpi ER; Kirch DG
    J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients.
    Tuason VB
    J Clin Psychiatry; 1986 Mar; 47(3):126-9. PubMed ID: 3512535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR; Hollister LE; Arnold KV; Earle GM
    Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.